HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Melatonin Dose Study, Steroid Warning Show Both Sides Of Coin For US Supplement Industry Image

Latest Public Perception Peril Prompted By JAMA Research Letter, FDA SARMs Consumer Alert

Executive Summary

Separate criticisms show opposite sides of the coin of public perception constantly flipping for businesses large and small making and marketing supplements available in US.

You may also be interested in...

‘Lack Of Understanding’ Here, Spiked Product There Add Up To US Supplement Industry Image Problem

Research suggesting FDA more stringently regulate claims for fish oil supplements impresses industry as another sign the agency’s regulation and the requirements fulfilled by compliant businesses aren’t appreciated or understood. FDA announcement of ED drugs in products labeled as supplements shows agency must be aware students are starting or returning to classes.

COVID-19 Stress Drives Anxiety-Reducing Supplement Sales Up 79% In US Since 2018

Sales for anxiety/stress relief dietary supplements in 2020 grew 79% from 2018, eclipsing growth of 22% for general herbal supplements during the same comparison period. Stress-relief supplements including St. John’s wart, ashwagandha and cannabinoids continue to grow in popularity.

Mandatory Recall Guidance Positions FDA For ‘Robust’ Use Of Authority

Final guidance on mandatory recall authority under FSMA specifies how FDA allows firms opportunities for voluntary recalls and evidence it may consider when deciding whether to mandate a recall. But a consumer advocacy group critical of FDA says the guidance adds nothing for protecting public health.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts